Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic ablation of adhesion ligands effectively averts rejection of allogeneic immune cells
    Meeting Abstract

    Hammer, Q.; Perica, K.; Mbofung, R. M.; Van Ooijen, H.; Goodridge, J. P.; Valamehr, B.; Önfelt, B.; Sadelain, M.; Malmberg, K. J.
    European Journal of Immunology (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Deconvoluting global cytokine signaling networks in natural killer cells
    Meeting Abstract

    Wiedemann, G. M.; Santosa, E. K.; Grassmann, S.; Sheppard, S.; Le Luduec, J. B.; Adams, N. M.; Dang, C.; Hsu, K. C.; Sun, J. C.; Lau, C. M.
    European Journal of Immunology (2022)

    Fulltext@MSK | Save
  • A mitochondrial long-chain fatty acid oxidation defect leads to transfer RNA uncharging and activation of the integrated stress response in the mouse heart
    Journal Article

    Ranea-Robles, P.; Pavlova, N. N.; Bender, A.; Pereyra, A. S.; Ellis, J. M.; Stauffer, B.; Yu, C.; Thompson, C. B.; Argmann, C.; Puchowicz, M.; more...
    Cardiovascular Research (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI
    Meeting Abstract

    Usmani, S. Z.; Martin, T. G.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; Munshi, N. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Patel, K.; Sano, D.; Maris, M.; Lesokhin, A. M.; Von Keudell, G.; Doucette, K.; Ramchandren, R.; Pavlov, D.; Uger, R. A.; Molloy, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma
    Meeting Abstract

    Patel, K.; Orlowski, R. Z.; Doucette, K.; Maris, M.; Pianko, M. J.; Ramchandren, R.; Stevens, D. A.; Vesole, D. H.; Uger, R. A.; Scheuber, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)
    Meeting Abstract

    Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodríguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1
    Meeting Abstract

    Jakubowiak, A. J.; Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save